Turmeric Acquisition Corp.
| IPO Proceeds, $M | $97.75M |
|---|---|
| IPO Date | Oct 16, 2020 |
| CEO | Luke Evnin, Ph.D. |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology with an emphasis on oncology and rare disease therapeutics |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Oct 20, 2022 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Turmeric Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 11 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Matthew Roden, Ph.D. | 50 | Chairman |
| David Meeker, M.D. | 65 | Director |
| Andrew Robbins, M.B.A. | 44 | Director |
| Mitchell H. Finer, Ph.D. | 61 | Director |
| Pablo Cagnoni, M.D. | 57 | Director |
| Luke Evnin, Ph.D. | 57 | Chief Executive Officer |
| Todd Foley, M.B.A. | 48 | President |
| Ed Hurwitz, J.D., M.B.A. | 56 | Chief Financial Officer |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Credit Suisse | Joint BR | 6,587,500 | units |
| JMP Securities | Joint BR | 1,912,500 | |
| 8,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Sep 28, 2020 | Initial S-1 |
| Oct 6, 2020 |
S-1/A Amendment #1
Sign In to view filing content. |
| Oct 7, 2020 |
S-1/A Amendment #2
Sign In to view filing content. |
| Oct 13, 2020 |
S-1/A Amendment #3
Sign In to view filing content. |
| Oct 15, 2020 |
PR announcing pricing of $85mm IPO
Sign In to view filing content. |
| Oct 16, 2020 | 424B4 IPO Prospectus |
| Oct 21, 2020 |
8-K announcing full over-allotment exercise
Sign In to view filing content. |
| Dec 4, 2020 |
8-K announcing separate trading of common stock and warrants
Sign In to view filing content. |
| Apr 30, 2021 |
8-K announcing change in directors
Sign In to view filing content. |
| Sep 19, 2022 |
PRE14A Preliminary proxy for charter extension meeting
Sign In to view filing content. |
| Oct 10, 2022 |
PR announcing liquidation and redemption of all public shares
Sign In to view filing content. |